EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Fenofibrate in ophthalmology: therapeutic efficacy and mechanisms

Sean Chung-Hei Ho, Isabelle Xin Yu Lee, Chang Liu, Mingyi Yu, Hong Chang Tan, Gavin Siew Wei Tan, Yu-Chi Liu

Journal of Pharmacy & Pharmaceutical Sciences · 2026

DOI: 10.3389/jpps.2026.16995 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2026. Verfasst von Sean Chung-Hei Ho und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Exeter Medical School, Exeter, United Kingdom. Hauptthemen laut MEDLINE: Fenofibrate, Eye Diseases, Hypolipidemic Agents. Die Arbeit nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ophthalmic diseases are a growing global cause of visual impairment, driven by population aging and the rising prevalence of diabetes mellitus. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist widely used for dyslipidemia, has emerged as a candidate for therapeutic repurposing in ophthalmology. This narrative review synthesizes current preclinical and clinical evidence on fenofibrate across anterior and posterior segment diseases, including diabetic corneal neuropathy, diabetic keratopathy, dry eye disease, corneal burns, Fuchs endothelial corneal dystrophy, diabetic retinopathy, diabetic macular edema, neovascular age-related macular degeneration, and central retinal artery occlusion. Across ocular disease models, fenofibrate demonstrates neuroprotective, vascular stabilizing, and tissue-remodeling effects. These actions appear to involve modulation of shared pathogenic pathways, including PPARα-dependentregulation of inflammatory signaling, mitochondrial and lipid metabolism, and preservation of epithelial, endothelial, neuronal, and vascular integrity. Clinical evidence is strongest for diabetic retinopathy, where randomized trials support a potential adjunctive role in slowing progression and reducing interventions in patients with early-to-moderate disease. Preliminary clinical evidence for diabetic corneal neuropathy is promising but limited, whereas data for dry eye disease, corneal burns, Fuchs endothelial corneal dystrophy, neovascular age-related macular degeneration, and retinal ischemic injury remains preclinical. Emerging experimental ocular delivery strategies may improve local bioavailability while reducing systemic exposure. Overall, fenofibrate represents a biologically plausible adjunctive ophthalmic therapy, but further randomized trials, mechanistic studies, pharmacokinetic evaluation, and long-term safety assessments are required to define its therapeutic role beyond diabetic retinopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FenofibrateEye DiseasesHypolipidemic AgentsHumansAnimalsPPAR alpha

Stichwörter der Autor:innen

diabetic corneal neuropathydiabetic retinopathyfenofibrateophthalmologyperoxisome proliferator-activated receptor alpha

Substanzen

FenofibrateHypolipidemic AgentsPPAR alpha

Autor:innen und Institutionen

  • University of Exeter Medical School, Exeter, United Kingdom.
  • Regenerative Therapy Group, Singapore Eye Research Institute, Singapore, Singapore.
  • Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.
  • Surgical Retina Department, Singapore National Eye Centre, Singapore, Singapore.
  • Department of Cornea, Singapore National Eye Centre, Singapore, Singapore.

Zitieren

APA

Ho, S. C., Lee, I. X. Y., Liu, C., Yu, M., Tan, H. C., Tan, G. S. W., & Liu, Y. C. (2026). Fenofibrate in ophthalmology: therapeutic efficacy and mechanisms. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2026.16995

Vancouver

Ho SC, Lee IXY, Liu C, Yu M, Tan HC, Tan GSW, et al. Fenofibrate in ophthalmology: therapeutic efficacy and mechanisms. Journal of Pharmacy & Pharmaceutical Sciences. 2026. doi:10.3389/jpps.2026.16995

BibTeX
@article{Ho2026,
  author = {Ho, Sean Chung-Hei and Lee, Isabelle Xin Yu and Liu, Chang and Yu, Mingyi and Tan, Hong Chang and Tan, Gavin Siew Wei and Liu, Yu-Chi},
  title = {Fenofibrate in ophthalmology: therapeutic efficacy and mechanisms},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2026},
  doi = {10.3389/jpps.2026.16995}
}
Kostenlos starten →